The Chiromatic Vitality Mattress

“By combining unparalleled research with German-engineered dimensional textiles, we have developed a clinical-grade technology and a luxury experience, all in one,” explained Bart Zoni, Managing Partner.

MORRISTOWN, N.J. (PRWEB)
September 25, 2019

Chiromatic, a Chiropractor- approved sleep innovation company, today announced the world’s first mattress to use LoomAir 3DTM technology.

The original pioneers of Chiropractic mattresses have re-launched their line with a revolutionary new technology that will mean better sleep for the 45 million Americans who suffer from back and neck pain. As the trailblazer in specific chiropractic mattress design since 1977, Chiromatic has continued to look for revolutionary ways to bring better products to their network of doctors and customers.

“We discovered that mattresses have not really evolved over the past 40 years.” stated Bart Zoni, Managing Partner. “We recognized the need for a sleep line that provides health benefits along with desired comfort and luxury.”

With the newest generation of Chiromatic mattresses using LoomAir 3D technology, Chiromatic has addressed the problems of traditional beds and can better meet the needs of those suffering from back and neck pain. Contrary to traditional beds and memory foams, which create more resistance as one sleeps, LoomAir 3D technology distributes pressure evenly to rid of any unwanted “hot spots” on the body and puts a stop to uneven lumbar support.

“We looked to the aerospace, medical device, and automotive technologies to find our inspiration,” explained Zoni. “By combining unparalleled research with German-engineered dimensional textiles, we have developed a clinical-grade technology and a luxury experience, all in one.”

The 3-dimensional fabrics provide a surface-body interface that is supportive throughout, but soft at the pressure points, adapting to any sleep position. Available in their new Vitality mattress, these 3D “spacer” fabrics have two faces separated by millions of tiny filaments, providing the support of over 3 million fibers to resemble the feeling of floating on air.

Vitality Mattress

Experience the healing power of sleep with Chiromatic’s advanced, proprietary support technology for those with back and neck pain. Comprised of non-toxic materials and compatible with adjustable bases, the exclusive patent pending technology available in this bed delivers:

• 
  A unique feeling of weightlessness and reduced point pressure
• Disruption-free motion for an ideal partner bed
• Even weight distribution and adaptive support for optimal alignment of the spine
• Increased airflow for optimal temperature control

“We believe a bed should be more than a piece of bedroom furniture – it should be the centerpiece of a healthy lifestyle,” explained Deb Pearce, Partner. “This technology marks a new era at Chiromatic that speaks to who we are as a company and is a direct reflection of the value we deliver to our clients – scientific, luxurious and technologically advanced.”

Taking a new and improved health-first approach, Chiromatic’s revitalized mission has evolved to promote the notion that sleep and health are one in the same. Their new line of mattresses and pillows are proven to improve the quality of sleep and specifically support those that live an active lifestyle. Products are available through a Chiropractor network as well as in their Morristown experience center, set to open this fall.

About Chiromatic

Since 1977, Chiromatic Sleep Systems have been designed with and trusted by Chiropractors and can be an important part of a holistic approach to managing back and neck pain. Approaching sleep with a health-first approach, Chiromatic uses the latest in clinical-grade technology, to innovate the mattress industry with sleep systems that address the needs of millions of consumers that experience back and neck pain – and those that just want the most comfortable night’s sleep.

For more information, please visit: https://www.chiromatic.com/

Share article on social media or email:

NISKAYUNA, N.Y. (PRWEB)
September 25, 2019

On May 6th, 2019, Martin, Harding & Mazzotti, LLP partner, Rosemarie Riddell Bogdan, was appointed to a leadership position on the Plaintiffs’ Personal Injury Steering Committee in the National Valsartan NDMA contamination litigation (IN RE: Valsartan Products Liability Litigation, MDL No. 2875) pending in federal court in New Jersey.  Ms. Bogdan will serve as the Co-Science Chair on the Plaintiff’s Personal Injury Steering Committee.

The IN RE: Valsartan Products Liability Litigation, MDL No. 2875 centers around the FDA recalls of Valsartan which began in July of 2018 and have continued throughout 2019. The FDA recall came after 22 other countries issued recalls of over 2,300 Valsartan batches.   Other batches of “sartan” medications, Losartan and Irbesartan, have been added to the FDA recall list.  As of September, 2018, there have been 1,152 individual recalls making this the largest Class 1 drug recall to date.   

The medications have been recalled because they contain nitrosamine impurities that don’t meet the FDA’s safety standards. Nitrosamines are organic chemical compounds that are comprised of a nitroso group bonded to an amine.   The nitrosamine impurities that have been found are Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA).  Most nitrosamines are carcinogenic.  In particular, NDMA, NDEA and NMBA are recognized by the International Agency for Research on Cancer to be carcinogens.  NDMA so reliably causes cancer that it is used to create cancer in rats for cancer research.  

Over 2 million Americans have received notices in the mail alerting them of the recalls and their potential exposure to a probable carcinogen. Similar warnings have also been issued by the World Health Organization (WHO), Health Canada, the European Medical Association (EMA), and the Hong Kong Department of Health.

Many lawsuits have been filed by patients across the U.S., for strict products liability, manufacturing defect, negligence, fraud, violation of warranties, and other laws relating to the safe sale and distribution of prescription drugs.  On February 14, 2019, the Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order consolidating valsartan products liability lawsuits in the District of New Jersey.  This process is intended to serve the convenience of the parties, witnesses, and the judicial system, and to reduce duplicative discovery, and avoid conflicting pretrial schedules. Future cases filed by patients claiming injuries caused by the contaminated Valsartan will be transferred or sued directly into the MDL.  This MDL is comprised of both personal injury cases, as well as class actions.  The MDL includes all manufacturers of the recalled valsartan.  A list of the medications that have been recalled can be found on the FDA’s website. 

Martin, Harding & Mazzotti, LLP® is a personal injury law firm whose practice is limited to protecting the rights of those wrongfully injured as a result of negligence. If you or a loved one have been injured, you can call our experienced team of attorneys toll-free at 1.800.LAW.1010 (1-800-529-1010).

Share article on social media or email:

“There’s a lot happening with the EU MDR… By leveraging some of the methods we suggest in this new white paper, we believe that will go a long way in helping these manufacturers streamline the transition.”

LEXINGTON, Mass. (PRWEB)
September 25, 2019

Cognition® Corporation, a software company specializing in medical device compliance and commercialization, has just released a new white paper on the upcoming implementation of the European Union’s Medical Device Regulation (EU MDR).

The MDR is a new regulatory framework for the oversight of medical devices submitted to and cleared for market in European Union Member States. Intended to replace the previous Medical Device Directive established in 1993, this new regulation is set to see full implementation in May 2020.

“The transition to this new system of regulatory compliance is going to be a challenge for medical device manufacturers,” says David Cronin, CEO of Cognition Corporation. “We’re releasing this paper in the hopes of helping some organizations understand and prepare for the changes ahead in the European market.”

The new white paper takes a high-level approach to the EU MDR, laying out the basics before diving into certain preparatory methods manufacturers of medical devices can undertake. Strategies such as planning ahead, keeping an eye on device classification, and ensuring robust risk management are reviewed.

“There’s a lot happening with the EU MDR,” says Mr. Cronin, “and even though it was published back in 2017, there are still organizations who have yet to come into compliance before the official implementation date. By leveraging some of the methods we suggest in this new white paper, we believe that will go a long way in helping these manufacturers streamline the transition.”

Mr. Cronin adds that the paper will offer suggestions for meeting the MDR’s robust postmarket surveillance requirements as well. “Just like the FDA, the EU is getting more concerned with the total product lifecycle,” says Mr. Cronin. “By highlighting this in our paper, we hope to bring more awareness, and hopefully give folks a chance to better understand what the EU MDR is all about.”

The white paper is available for download here.

Cognition® Corporation, based in Lexington, Massachusetts, has offered solutions for product development compliance for more than fifteen years. Cognition offers the Cognition Cockpit® Platform, along with engineering and validation support, and industry expertise. Thousands of users worldwide use Cognition solutions to manage their product development process and meet regulatory, performance, and-time to-market goals. For more information, visit http://www.cognition.us or call (781) 271-9300.

Share article on social media or email: